A detailed history of Allspring Global Investments Holdings, LLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 151,596 shares of VNDA stock, worth $757,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151,596
Previous 151,428 0.11%
Holding current value
$757,980
Previous $855,000 16.96%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$4.61 - $6.34 $774 - $1,065
168 Added 0.11%
151,596 $710,000
Q2 2024

Jul 26, 2024

SELL
$3.91 - $6.5 $35,358 - $58,779
-9,043 Reduced 5.64%
151,428 $855,000
Q1 2024

Apr 18, 2024

SELL
$3.47 - $4.61 $314,611 - $417,970
-90,666 Reduced 36.1%
160,471 $659,000
Q4 2023

Jan 25, 2024

SELL
$3.38 - $4.58 $211,189 - $286,167
-62,482 Reduced 19.92%
251,137 $1.06 Million
Q3 2023

Oct 27, 2023

BUY
$4.28 - $6.57 $1.34 Million - $2.06 Million
313,619 New
313,619 $1.35 Million
Q2 2023

Jul 18, 2023

SELL
$5.9 - $6.95 $3.52 Million - $4.15 Million
-596,912 Reduced 74.86%
200,480 $1.32 Million
Q1 2023

Apr 13, 2023

BUY
$6.18 - $7.99 $3.49 Million - $4.52 Million
565,510 Added 243.88%
797,392 $5.41 Million
Q4 2022

Jan 23, 2023

BUY
$6.87 - $10.96 $274,236 - $437,501
39,918 Added 20.79%
231,882 $1.71 Billion
Q3 2022

Oct 26, 2022

BUY
$9.44 - $11.76 $1.79 Million - $2.22 Million
189,173 Added 6777.96%
191,964 $1.9 Million
Q2 2022

Jul 25, 2022

SELL
$9.31 - $11.84 $754,156 - $959,099
-81,005 Reduced 96.67%
2,791 $30,000
Q1 2022

May 02, 2022

SELL
$10.84 - $16.55 $186,242 - $284,345
-17,181 Reduced 17.01%
83,796 $947,000
Q4 2021

Jan 28, 2022

BUY
$15.69 - $21.14 $1.58 Million - $2.13 Million
100,977 New
100,977 $1.58 Million

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $283M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.